Humacyte Inc is trading 5% down at $0.88 as investors continue to react to the company's recently priced public offering of common stock.
- The stock has been sliding for several sessions following the announced deal, which adds significant dilution pressure to existing shares.
- Trading today appears driven by the ongoing digestion of the financing terms, as no fresh company news has been released to offset the cautious market tone.